Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7412881 | 0.92 | CYP19A1 (0.41) | CYP19A1SMN1; SMN2ALDH1A1MAPTTSHR | |
| SCHEMBL28248440 | 0.88 | CYP19A1 (0.46) | CYP19A1SMN1; SMN2ALDH1A1MAPTTSHR | |
| SCHEMBL5728797 | 0.84 | CYP19A1 (0.43) | CYP19A1SMN1; SMN2ALDH1A1MAPTTSHR | |
| SCHEMBL30252315 | 0.84 | CYP19A1 (0.43) | CYP19A1SMN1; SMN2ALDH1A1MAPTTSHR | |
| SCHEMBL28248935 | 0.84 | CYP19A1 (0.46) | CYP19A1SMN1; SMN2ALDH1A1MAPTTSHR | |
| SCHEMBL6961355 | 0.81 | NAAA (0.46) | MAPTTSHRFFAR1FAAH | |
| SCHEMBL6680392 | 0.81 | LIPG (0.53) | TSHRLIPG | |
| SCHEMBL3629719 | 0.81 | LIPG (0.53) | TSHRLIPG | |
| SCHEMBL6952873 | 0.81 | NAAA (0.46) | MAPTTSHRFFAR1FAAH | |
| SCHEMBL6685317 | 0.81 | LIPG (0.53) | TSHRLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388542-A1 | ANALOGUES OF PENTAMIDINE AND USES THEREFOR | AURANSA INC. (US) | 2025-12-25 | — | — | US | disclosed |
| CN-113766914-B | Pentaneamidine analogues and uses thereof | 美商奥润沙公司 | 2024-02-13 | — | — | CN | disclosed |
| US-20220144776-A1 | ANALOGUES OF PENTAMIDINE AND USES THEREFOR | AURANSA INC. | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388542-A1 | ANALOGUES OF PENTAMIDINE AND USES THEREFOR | MALT1, SLC38A7, SLC7A1 | CYP19A1 2551/4885SMN1; SMN2 897/4885ALDH1A1 1716/4885 |
| US-20220144776-A1 | ANALOGUES OF PENTAMIDINE AND USES THEREFOR | DPYD, TYMP, GOT1 | CYP19A1 3284/4885SMN1; SMN2 1570/4885ALDH1A1 719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.